| Detailed information |
|---|
| CancerLivER ID | 2467 |
| Biomarker | GRP94, GRP78, GRP75, HSC71, HSP90, HSP70, HSP60, Aconitase, EF-2, Nucleophosmin, VIM, NDK-A, Argininosuccinate synthase, CPSASE-I, |
| Biomarker Name/Symbol (given in Publication) | 14-proteins signature (GRP94, GRP78, GRP75, HSC71, HSP90, HSP70, HSP60, Aconitase, EF-2, Nucleophosmin, Vimentin, Nucleoside diphosphate kinase A (NDK A), Argininosuccinate synthase, Carbamoyl-phosphate synthase (CPSASE I) ) |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Potential biomarker for all type HCC associated; but not validated on independent dataset |
| Experimental Condition | HCC tumor v/s non-tumorous |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Differentially expressed (Argininosuccinate synthase, Carbamoyl-phosphate synthase (CPSASE I) are Downregulated and rest 12 are Upregulated) in HCC tumor v/s non-tumorous |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 14654528 |
| Type of Biomarker | Diagnostic |
| Pathway | NA |
| Cohort | Paired tumorous and surrounding nontumorous tissues obtained from 21 HCC patients. They were divided into three HCC types by viral markers: 7 hepatitis B surface antigen-positive (B-type HCC), 7 anti-HCV-positive (C-type HCC), and 7 hepatitis B surface antigen-negative and anti-HCV-negative. |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | all type HCC |
| Year of Publication | 2003 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |